The effector property of IL-1β-dependent Th17 cells is due to their high glycolytic capacity since generating IL-1β-dependent Th17 cells in pyruvate-containing media impairs glycolysis as well as its anti-tumor potential [87]. The gene discussed is IL1B; the disease is neoplasm.